![](https://monteverdelaw.com/wp-content/uploads/case-logo/cerevel-therapeutics-holdings-inc.png)
Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), relating to its proposed sale to AbbVie Inc. Under the terms of the agreement, CERE shareholders are expected to receive $45.00 in cash per share they own.
Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE), relating to its proposed sale to AbbVie Inc. Under the terms of the agreement, CERE shareholders are expected to receive $45.00 in cash per share they own.